ctrum (Ptot) is an estimation of the global activity of the ANS.

Spontaneous cardiac BRS was calculated using the sequences method [24] and the cross-spectral analysis method [21]. A 15-minute simultaneous recording of the electrocardiogram, blood pressure and ventilation was performed at rest in the supine position. Finger arterial blood pressure was measured using a noninvasive continuous blood pressure monitor (Finapress 2300, Ohmeda). The plethysmographic cuff was placed around the middle phalanx of the finger and the cuff pressure was modulated to maintain transmural pressure at zero. Then, RR intervals were calculated and each RR interval was paired with the corresponding systolic pressure wave. To determine spontaneous cardiac BRS, the linear regression slope was calculated for each sequence of at least three or more successive heart beats in which there were concordant increases or decreases in systolic blood pressure and RR interval. Cardiac BRS (expressed in milliseconds per millimeter of mercury) was calculated as the mean of the slopes of all sequences. The cross-spectral analysis method was used on the same recordings. BRS was calculated as the ratio between the transfer function moduli of arterial blood pressure and HRV, for the frequencies between 0.04 and 0.15 Hz (aLF) and between 0.15 and 0.40 Hz (aHF). The value was considered to be validated when the coherence between arterial blood pressure and HRV was greater than 0.5.

Ambulatory systolic arterial blood pressure (SBP), diastolic arterial blood pressure (DBP), and mean arterial blood pressure (MBP) were assessed using a 24-hour ambulatory Holter recorder based on the auscultatory method (Diasys Integra, Novacor, Rueil-Malmaison, France).

2.3. Statistics

The data were analyzed using the SPSS software.

3. RESULTS

Demographic data and clinical characteristics at time of ANS activity evaluation are presented in Table 1. Peripheral pain and hypohidrosis were reported by all patients. Six patients in the age range of 43 to 64 years all had CKD, cardiac hypertrophy, and one had severe neurovascular disease. Of the other patients, one young adult male who had no residual enzyme activity had been identified through family screening (patient 1) and had yet no signs of organ complications. In contrast, a 62- year-old female patient (patient 9) had 50% residual enzyme activity despite a large GLA gene deletion. She had been diagnosed at 30 years old and had progressed to end-stage renal disease (ESRD) necessitating kidney transplantation at age 41. Her respiratory insufficiency was believed to be due to Fabry disease. A third patient (patient 4, 51-year-old female, 30% residual activity) only had a cardiac conduction abnormality and was not commenced on ERT.

Table 2 presents the autonomic nervous system activity indices. Sympathetic activity was conserved, as indicated by normal SDNN (mean 136.2 ± 46.3 ms) and SDANN (mean 91.0 ± 48.3 ms) values. Although the mean LF/HF ratio (2.96 ± 2.29) was found within the expected range, the results from 3 patients were suggestive of ANS disbalance. The parasympathetic activity, however, varied widely with pNN50 ranging from 1.8% to 46.8%, HF from 36 to 4009 msec2/Hz, and BRS from 0.69 to 19.78 ms/mmHg. The LF/HF ratio spanned from 0.91 to 7.66. The VLFI index was frequently elevated, up to 6.90, and the value was above the threshold of 4.2 in 3 patients.

A single patient (patient 9) had a very low Ptot, as assessed by temporal analysis, and low sympathetic and parasympathetic indices (Fourier transform) with a LF/ HF ratio reaching 1.92 and a severely depressed BRS slope value. This particular patient had progressed to ESRD. The youngest patient had no signs of organ failure and exhibited the highest Ptot and BRS.

Blood pressure values were relatively low in all patients necessitating careful titration of ACEI therapy (6 patients) to avoid hypotensive side effects. Mean systolic blood pressure was 103 ± 10 mmHg and mean diastolic blood pressure 66 ± 5 mmHg.

In this small population, a significant positive correlation was found between glomerular filtration rate (GFR) and BRS (p < 0.05; r = 0.75, Figure 1), while there were no correlations with other ANS variables. Gender, age, proteinuria, left ventricular mass and arterial blood pressure all did not significantly correlate with ANS indices. However, there was a tendency for the severity of proteinuria to correlate with left ventricular mass (r = 0.66; p = 0.051).

4. DISCUSSION

We describe the results of quantitative measurements of ANS in 9 patients with Fabry disease. ANS indices (HRV, spontaneous BRS, and ambulatory blood pressure), analyzed using established methods [19-21,24], varied considerably between the individuals. The indices of global

Table 1. Demographics and clinical characteristics of 9 patients with Fabry disease.

Table 2. Autonomic nervous system activity indices in 9 patients with Fabry disease.

Figure 1. Correlation between baroreflex and glomerular filtration rate (p < 0.05; r = 0.75).

activity (Ptot, and in particular LF) were frequently high, while ANS balance was disturbed only in a few patients as indicated by an abnormal LF/HF ratio. Although sympathetic nervous system parameters (SDNN, SDANN) were within normal ranges, indices of parasympathetic parameters (i.e. pNN50, HF, BRS) were highly variable in our cohort.

Hilz et al. have previously reported that baroreflexmediated vasoconstriction can be deficient in patients with Fabry disease due to sympathetic vasomotor nerve fiber dysfunction [13]. In our study, BRS values were found to be strongly correlated with GFR. Neither sex nor age was associated with parasympathetic activity and there was no association with cardiac hypertrophy or rhythm abnormalities. Deficient BRS in relation with decline in GFR has been previously described in patients with chronic renal failure, regardless of the underlying renal disorder [25]. Sympathetic nervous system activation of the sympathetic nervous system has been reported to be an important feature contributing to renal injury [26-29], in part through its concomitant adverse effects on hypertension [30]. Six of our patients had CKD and had undergone kidney biopsy showing typical Gb3 deposition in the mesangial cells, endothelial cells and in podocytes. Yet, sympathetic nervous system indices were normal in all patients and blood pressures were low. Of note, systemic blood pressure has been found above the target level of 130/80 mmHg in substantial proportions of patients with Fabry disease [17].

HRV indices varied considerably in our patients. Decreased HRV has been reported in young patients with Fabry disease and is believed to reflect a reduction in parasympathetic stimulation of the heart [7]. Longitudinal studies in the general population have documented the predictive value of low HRV for an adverse cardiac prognosis [31,32]. In particular, reduced ANS activity evaluated through HRV indices were independently associated with an increased risk of myocardial infarction, congestive heart failure, death from cardiovascular disease, and total mortality [31-33].

Little is known about the mechanisms underlying disturbances of ANS activity in Fabry disease, but multiple factors are believed to contribute to ischemic neural damage, including narrowing of neural small blood vessels due to vascular endothelial Gb3 storage, loss of smooth muscle resiliency, and thrombotic complications [34]. A recent questionnaire study used the Autonomic Symptom Profile to prospectively evaluate ANS activity in 48 Fabry patients [35]. The investigators disputed the role of neuropathy in Fabry-related autonomic dysfunction based on their findings which included a low prevalence of orthostatic intolerance and normal cardiovascular autonomic function. Therefore, they dispute the role of neuropathy in Fabry-related autonomic dysfunction, and suggest a key role of organ failure was suggested to play a key role in development of signs of autonomic dysfunction. Of note, a patient questionnaire is a disputable method of quantifying ANS activity.

Currently, there is no undisputable biomarker for disease burden of phenotypic diversity in Fabry disease [9]. Urinary Gb3 has been reported to correlate with clinical presentation but is a rather demanding test to perform [36]. Scoring systems, including an age-adjusted scoring system, have been developed to assess the overall severity of Fabry disease and progression over time [37-39], but they are not useful for evaluating ANS activity. Although the sample size of our study does not allow drawing firm conclusions, assessing ANS activity may contribute to comprehensive staging of Fabry disease. If our results are confirmed by larger studies, it may assist in identifying patients at high risk of developing renal and cardiac events, and can be useful tool in non-invasive monitoring of patients on and off treatment.

5. ACKNOWLEDGEMENTS

The authors would like to acknowledge the editorial support of Hans Ebels, MD, from Genzyme Corporation. The authors maintain full and independent responsibility for the content of this manuscript.

REFERENCES

  1. Zarate, Y. and Hopkin, R. (2008) Fabry’s disease. The Lancet, 372, 1427-1435. doi:10.1016/S0140-6736(08)61589-5
  2. Najafian, B., Svarstad, E., Bostad, L., Gubler, M.C., Tondel, C., et al. (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney International, 79, 663- 670. doi:10.1038/ki.2010.484
  3. Ramaswami, U., Najafian, B., Schieppati, A., Mauer, M. and Bichet, D.G. (2010) Assessment of renal pathology and dysfunction in children with Fabry disease. Clinical Journal of the American Society of Nephrology, 5, 365- 370. doi:10.2215/CJN.08091109
  4. Tondel, C., Bostad, L., Hirth, A. and Svarstad, E. (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. American Journal of Kidney Diseases, 51, 767-776. doi:10.1053/j.ajkd.2007.12.032
  5. Schiffmann, R., Hauer, P., Freeman, B., Ries, M., Scott, L.J., et al. (2006) Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle & Nerve, 34, 53-56. doi:10.1002/mus.20550
  6. Wanner, C., Oliveira, J.P., Ortiz, A., Mauer, M., Germain, D.P., et al. (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: Natural history data from the Fabry registry. Clinical Journal of the American Society of Nephrology, 5, 2220-2228. doi:10.2215/CJN.04340510
  7. Kampmann, C., Wiethoff, C.M., Whybra, C., Baehner, F.A., Mengel, E., et al. (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatrica, 97, 463-469. doi:10.1111/j.1651-2227.2008.00700.x
  8. Breunig, F., Weidemann, F., Strotmann, J., Knoll, A. and Wanner, C. (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney International, 69, 1216-1221. doi:10.1038/sj.ki.5000208
  9. Schiffmann, R., Waldek, S., Benigni, A. and Auray-Blais, C. (2010) Biomarkers of Fabry disease nephropathy. Clinical Journal of the American Society of Nephrology, 5, 360-364. doi:10.2215/CJN.06090809
  10. Wilcox, W.R., Oliveira, J.P., Hopkin, R.J., Ortiz, A., Banikazemi, M., et al. (2008) Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry registry. Molecular Genetics and Metabolism, 93, 112-128. doi:10.1016/j.ymgme.2007.09.013
  11. Cable, W.J., Kolodny, E.H. and Adams, R.D. (1982) Fabry disease: Impaired autonomic function. Neurology, 32, 498-502. doi:10.1212/WNL.32.5.498
  12. Dutsch, M., Marthol, H., Stemper, B., Brys, M., Haendl, T., et al. (2002) Small fiber dysfunction predominates in Fabry neuropathy. Journal of Clinical Neurophysiology, 19, 575-586. doi:10.1097/00004691-200212000-00011
  13. Hilz, M.J., Marthol, H., Schwab, S., Kolodny, E.H., Brys, M., et al. (2010) Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. Journal of Hypertension, 28, 1438-1448. doi:10.1097/HJH.0b013e328336a077
  14. Pintos-Morell, G. and Beck, M. (2009) Fabry disease in children and the effects of enzyme replacement treatment. European Journal of Pediatrics, 168, 1355-1363. doi:10.1007/s00431-009-0937-9
  15. Lidove, O., West, M.L., Pintos-Morell, G., Reisin, R., Nicholls, K., et al. (2010) Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature. Genetics in Medicine, 12, 668-679. doi:10.1097/GIM.0b013e3181f13b75
  16. Schaefer, R.M., Tylki-Szymanska, A. and Hilz, M.J. (2009) Enzyme replacement therapy for Fabry disease: A systematic review of available evidence. Drugs, 69, 2179- 2205. doi:10.2165/11318300-000000000-00000
  17. Ortiz, A., Oliveira, J.P., Wanner, C., Brenner, B.M., Waldek, S., et al. (2008) Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nature Reviews Nephrology, 4, 327-336. doi:10.1038/ncpneph0806
  18. Weidemann, F., Linhart, A., Monserrat, L. and Strotmann, J. (2010) Cardiac challenges in patients with Fabry disease. International Journal of Cardiology, 141, 3-10. doi:10.1016/j.ijcard.2009.08.002
  19. Malik, M. (1996) Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task force of the European society of cardiology and the North American society of pacing and electrophysiology. Circulation, 93, 1043-1065.
  20. Pichot, V., Gaspoz, J.M., Molliex, S., Antoniadis, A., Busso, T., et al. (1999) Wavelet transform to quantify heart rate variability and to assess its instantaneous changes. Journal of Applied Physiology, 86, 1081-1091.
  21. Cerutti, C., Barres, C. and Paultre, C. (1994) Baroreflex modulation of blood pressure and heart rate variabilities in rats: Assessment by spectral analysis. American Journal of Physiology, 266, H1993-H2000.
  22. Akselrod, S., Gordon, D., Ubel, F.A., Shannon, D.C., Berger, A.C., et al. (1981) Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control. Science, 213, 220-222. doi:10.1126/science.6166045
  23. Pagani, M., Lombardi, F., Guzzetti, S., Rimoldi, O., Furlan, R., et al. (1986) Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circulation Research, 59, 178-193.
  24. Parlow, J., Viale, J.P., Annat, G., Hughson, R. and Quintin, L. (1995) Spontaneous cardiac baroreflex in humans. Com- parison with drug-induced responses. Hypertension, 25, 1058-1068.
  25. Bavanandan, S., Ajayi, S., Fentum, B., Paul, S.K., Carr, S.J., et al. (2005) Cardiac baroreceptor sensitivity: A prognostic marker in predialysis chronic kidney disease patients? Kidney International, 67, 1019-1027. doi:10.1111/j.1523-1755.2005.00165.x
  26. Blankestijn, P.J. (2004) Sympathetic hyperactivity in chronic kidney disease. Nephrology Dialysis Transplantation, 19, 1354-1357. doi:10.1093/ndt/gfh242
  27. Foley, R.N., Parfrey, P.S. and Sarnak, M.J. (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases, 32, S112-S119. doi:10.1053/ajkd.1998.v32.pm9820470
  28. Furuland, H., Linde, T., Englund, A. and Wikstrom, B. (2008) Heart rate variability is decreased in chronic kidney disease but may improve with hemoglobin normalization. Journal of Nephrology, 21, 45-52.
  29. Koomans, H.A., Blankestijn, P.J. and Joles, J.A. (2004) Sympathetic hyperactivity in chronic renal failure: A wakeup call. Journal of the American Society of Nephrology, 15, 524-537. doi:10.1097/01.ASN.0000113320.57127.B9
  30. Masuo, K., Lambert, G.W., Esler, M.D., Rakugi, H., Ogihara, T., et al. (2010) The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hpertension Research, 33, 521-528. doi:10.1038/hr.2010.35
  31. Bigger, J.T. Jr., Fleiss, J.L., Steinman, R.C., Rolnitzky, L.M., Kleiger, R.E., et al. (1992) Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation, 85, 164-171.
  32. Tsuji, H., Larson, M.G., Venditti, F.J. Jr., Manders, E.S., Evans, J.C., et al. (1996) Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation, 94, 2850-2855.
  33. Kleiger, R.E., Miller, J.P., Bigger, J.T. Jr. and Moss, A.J. (1987) Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. American Journal of Cardiology, 59, 256-262. doi:10.1016/0002-9149(87)90795-8
  34. Rombach, S.M., Twickler, T.B., Aerts, J.M., Linthorst, G.E., Wijburg, F.A., et al. (2010) Vasculopathy in patients with Fabry disease: Current controversies and research directions. Molecular Genetics and Metabolism, 99, 99-108. doi:10.1016/j.ymgme.2009.10.004
  35. Biegstraaten, M., van Schaik, I.N., Wieling, W., Wijburg, F.A. and Hollak, C.E. (2010) Autonomic neuropathy in Fabry disease: A prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC Neurology, 10, 38. doi:10.1186/1471-2377-10-38
  36. Auray-Blais, C., Cyr, D., Ntwari, A., West, M.L., CoxBrinkman, J., et al. (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Molecular Genetics and Metabolism, 93, 331-340. doi:10.1016/j.ymgme.2007.10.001
  37. Beck, M. (2006) The Mainz Severity Score Index (MSSI): Development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatrica, 95, 43-46. doi: 10.1111/j.1651-2227.2006.tb02388.x
  38. Giannini, E.H., Mehta, A.B., Hilz, M.J., Beck, M., Bichet, D.G., et al. (2010) A validated disease severity scoring system for Fabry disease. Molecular Genetics and Metabolism, 99, 283-290. doi:10.1016/j.ymgme.2009.10.178
  39. Hughes, D.A., Ramaswami, U., Barba Romero, M.A. and Deegan, P. (2010) Age adjusting severity scores for Anderson-Fabry disease. Molecular Genetics and Metabolism, 101, 219-227. doi:10.1016/j.ymgme.2010.06.002

NOTES

*Disclosures: None.

#Corresponding author.

Journal Menu >>